Patient (pt) Experiences of Receiving Idecabtagene Vicleucel (Ide-Cel, Bb2121) Versus Standard (std) Regimens for the Treatment (tx) of Relapsed/Refractory Multiple Myeloma (RRMM) in the Randomized, Controlled KarMMa-3 Clinical Trial: Analysis of Longitudinal Qualitative Interviews